162 related articles for article (PubMed ID: 19596645)
1. First-line chemotherapy for metastatic breast cancer.
Telli ML; Carlson RW
Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S66-72. PubMed ID: 19596645
[TBL] [Abstract][Full Text] [Related]
2. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
Conlin AK; Seidman AD
Clin Breast Cancer; 2008 Jun; 8(3):215-23. PubMed ID: 18650151
[TBL] [Abstract][Full Text] [Related]
3. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Gligorov J; Lotz JP
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():53-66. PubMed ID: 19101794
[TBL] [Abstract][Full Text] [Related]
4. Treating metastatic breast cancer with systemic chemotherapies: current trends and future perspectives.
Smith NZ
Clin J Oncol Nurs; 2012 Apr; 16(2):E33-43. PubMed ID: 22459535
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
8. Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.
Ocaña A; Hortobagyi GN; Esteva FJ
Clin Breast Cancer; 2006 Feb; 6(6):495-504. PubMed ID: 16595032
[TBL] [Abstract][Full Text] [Related]
9. Maintenance treatment in metastatic breast cancer.
Sánchez-Muñoz A; Pérez-Ruiz E; Ribelles N; Márquez A; Alba E
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1907-12. PubMed ID: 19046111
[TBL] [Abstract][Full Text] [Related]
10. Personalizing therapy for metastatic breast cancer.
Morris PG; Hudis CA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1223-6. PubMed ID: 19761426
[TBL] [Abstract][Full Text] [Related]
11. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
[TBL] [Abstract][Full Text] [Related]
12. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
Mahtani RL; Stein A; Vogel CL
Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
[TBL] [Abstract][Full Text] [Related]
13. Extending survival with chemotherapy in metastatic breast cancer.
O'Shaughnessy J
Oncologist; 2005; 10 Suppl 3():20-9. PubMed ID: 16368868
[TBL] [Abstract][Full Text] [Related]
14. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
Colozza M; de Azambuja E; Personeni N; Lebrun F; Piccart MJ; Cardoso F
Oncologist; 2007 Mar; 12(3):253-70. PubMed ID: 17405890
[TBL] [Abstract][Full Text] [Related]
15. First-line chemotherapy for metastatic breast cancer in patients ≥75 years: a retrospective single-centre analysis.
Debled M; Madranges N; Mertens C; Durand M; Brouste V; Brain E; Mauriac L
Crit Rev Oncol Hematol; 2011 Oct; 80(1):171-9. PubMed ID: 21036058
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the treatment of metastatic breast cancer.
Gralow JR
Breast Cancer Res Treat; 2005; 89 Suppl 1():S9-S15. PubMed ID: 15770536
[TBL] [Abstract][Full Text] [Related]
17. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
19. A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer.
Kemp Z; Jones A
Adv Ther; 2011 Aug; 28(8):603-14. PubMed ID: 21833702
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
